We’re hitting the slopes of the Dolomites and the small hamlet of Alagna Valsesia at the foot of the Monte Rosa massif.
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is ...
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback